2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Cure Parkinson’s Fundraising Heroes: April 2025
Half marathons were popular with our fundraising heroes in April, along with an incredible bike ride and a charity concert. Running for Team Cure In April, many of our supporters laced up their trainers to represent Team Cure at half marathons across the country. Fundraisers…
New findings from the TransEuro cell replacement trial are now published
Parkinson’s is characterised by the progressive loss of dopamine nerve cells (neurons) in an area of the brain associated with movement. Therefore, researchers have been investigating whether cell transplantations have potential to replace the neurons lost, to slow or reverse progression of the condition. What…
Paws for Parkinson’s: April Dog Walking Challenge raises over £39k for Cure Parkinson’s
Over 130 supporters and their dogs got out in the spring sunshine to take part in our 2025 April Dog Walking Challenge! For the past three years our supporters and their four-legged friends have ventured outdoors during the month of April to help fundraise for…
Over £268k raised for Cure Parkinson’s at the 2025 TCS London Marathon
On Sunday 27 April, 42 incredible Cure Parkinson’s supporters completed the grueling 26.2 mile race. Team Cure were battling the heat at the 45th London Marathon, but despite the difficult conditions each and every one of our determined runners crossed the finish line. Of the…
Cure Parkinson’s welcomes a new research committee chair
Every research project that Cure Parkinson’s funds must be recommended by our research committee – an independent board of leading Parkinson’s researchers, clinicians, people with Parkinson’s, patient advocates and experts in intellectual property and regulatory affairs, who meet four times a year to evaluate new…